Mukesh Verma, Ph.D.
Branch Chief, Methods and Technologies Branch

Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, Rm. 4E102, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)


  • Ph.D. - Host-virus Interaction
    Banaras Hindu University
  • M.Sc. - Biochemistry (Major) and Microbiology (Minor)
    Pantnagar University
  • B.Sc. - Biological Sciences
    Meerut University

Interest Areas

  • Biomarkers
  • Epigenetics
  • Epidemiology Technologies
  • Proteomics
  • MicroRNA
  • Methylation
  • Mitochondria
  • Nanotechnology
  • Risk Assessment
  • Susceptibility Factors
  • Systems Genetics
  • Metabolomics
  • Microbiome


Dr. Verma is Chief of the Epidemiology and Genomics Research Program's (EGRP) Methods and Technologies Branch (MTB), and oversees its research portfolio and initiatives that focus on methods to address epidemiologic data collection, study design and analysis, and to modify technological approaches developed in the context of other research endeavors for use as biomarkers and methods to understand cancer susceptibility.

He is responsible for stimulating EGRP-funded research on epigenetic approaches in cancer epidemiology and has been instrumental in developing epigenetics research for NIH as a whole. Dr. Verma helped to develop a Request for Applications (RFA) on Environmental Influences on Epigenetics with the National Institute of Environmental Health Sciences (NIEHS) and represents the Division of Cancer Control and Population Sciences (DCCPS), in NIH's Roadmap Initiative on EpigeneticsExternal Web Site Policy. He helped develop an RFA on Comparative Systems Genetics of Cancer with NCI's Division of Cancer Biology (DCB), and is known within the extramural research community as an EGRP Program Director for Program Announcements (PAs) on Small Grants for Cancer Epidemiology and Pilot Studies in Pancreatic Cancer. He also organized a workshop to explore developing a concept for a research initiative on mitochondrial DNA and cancer epidemiology.

Dr. Verma was, and continues to be, a co-Program Director for initiatives in gene-environment interactions in cancer etiology, including the Breast and Prostate Cancer and Hormone-Related Variants Cohort Consortium (BPC3), which is a collaborative project to pool data and biospecimens from a group of large prospective cancer epidemiology cohorts.

Dr. Verma joined EGRP as a Program Director in 2004. In 2005, he was appointed Acting Chief of EGRP's former Analytic Epidemiology Research Branch (AERB). When EGRP reorganized in 2007, he was appointed Acting Chief of MTB and of the former Host Susceptibility Factors Branch (HSFB), for which he served as Acting Chief through 2008. Before joining EGRP, he was a Program Director in NCI's Division of Cancer Prevention (DCP), where he worked in the areas of biomarkers, early detection, risk assessment, and prevention. He also was Coordinator of DCP's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs. He was on the faculty in the Biochemistry Department of Georgetown University before joining NIH.


Carrick DM, Chaturvedi A, Shiels MS, Divi, R, Filipski, KK, Hebert E, Verma M, Hildesheim A. Using immune marker panels to evaluate the role of inflammation in cancer: summary of an NCI-sponsored workshopExternal Web Site Policy. Cancer Epidemiol Biomarkers Prev. 2015 Jun. Epub ahead of print.

Chai RC, Lambie D, Verma M, Punyadeera C. Current trends in the etiology and diagnosis of HPV-related head and neck cancersExternal Web Site Policy. Cancer Med. 2015 Apr;4(4):596-607.

Hebert E, Rao LD, Verma M. Microbiome analysis: trends in cancer epidemiology, challenges and opportunitiesExternal Web Site Policy. Int J Cancer Res Mol Mech. 2015 Apr;1:1-5.

Verma M, Lam TK, Hebert E, Divi RL. Extracellular vesicles: potential applications in cancer diagnosis, prognosis, and epidemiologyExternal Web Site Policy. BMC Clin Pathol. 2015 Apr;15:6.

Verma M, Banerjee HN. Metabolomics approaches in cancer epidemiologyExternal Web Site Policy. Diseases. 2015;3:167-175

Verma M. The role of epigenomics in the study of cancer biomarkers in the development of diagnostic toolsExternal Web Site Policy. Adv Exp Med Biol. 2015;867:59-80.

Verma M. Epigenetic regulation of HIV, AIDS, and AIDS-related malignanciesExternal Web Site Policy. Methods Mol Biol. 2015;1238:381-403.

Vedham V, Verma M. Cancer-associated infectious agents and epigenetic regulationExternal Web Site Policy. Methods Mol Biol. 2015;1238:333-54.

Litzelman K, Verma M. Epigenetic regulation in biopsychosocial pathwaysExternal Web Site Policy. Methods Mol Biol. 2015;1238:549-67.

Verma M. Toxicoepigenomics and cancer: implications for screeningExternal Web Site Policy. Methods Mol Biol. 2015;1238:355-67.

Haznadar M, Mette E, Maruvada P, Milner J, Moore SC, Nicastro HL, Sampson JN, Verma M, Su LJ, Zanetti KA. Navigating the road ahead: addressing challenges for use of metabolomics in epidemiology studiesExternal Web Site Policy. Metabolomics. 2014 Apr;10(2):176-178.

Verma M, Rogers S, Divi RL, Schully SD, Nelson S, Su L, Ross SA, Pilch S, Winn DM, Khoury MJ. Epigenetic research in cancer epidemiology: trends, opportunities, and challengesExternal Web Site Policy. Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):223-33.

Verma M. Molecular profiling and companion diagnostics: where is personalized medicine in cancer heading?External Web Site Policy Per Med. 2014;11(8):761–771.

Return to Top